Ether

Ether

SCHEMBL778289

CCOCC.OCC(Cl)Cl

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
TSHR P16473 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL4944310 0.84 ALDH1A1 (0.45) ALDH1A1TSHR
Ether SCHEMBL6553095 0.80 ALDH1A1 (0.43) ALDH1A1
Ether SCHEMBL28705136 0.80
Ether SCHEMBL422163 0.80 ALDH1A1 (0.40) ALDH1A1TSHR
Alcohol SCHEMBL7158313 0.79
Ether SCHEMBL8089271 0.79 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL2837591 0.79 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL9750502 0.79
Ether SCHEMBL3794585 0.79 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL3701280 0.79 ALDH1A1 (0.37) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240165118-A1 Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids Sumitomo Pharma Co., Ltd. (JP) 2024-05-23 US disclosed
US-11957684-B2 Treatment of heavy menstrual bleeding associated with uterine fibroids SUMITOMO PHARMA SWITZERLAND GMBH (CH) 2024-04-16 US disclosed
CN-117659083-A Self-assembled monolayer material based on conjugated connecting groups, preparation method of self-assembled monolayer material and solar cell 南方科技大学 2024-03-08 CN disclosed
US-11918583-B2 2024-03-05 US disclosed
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-12-07 US disclosed
CN-110143999-B Cytotoxic and antimitotic compounds and methods of use thereof 酵活英属哥伦比亚省公司 2023-12-05 CN disclosed
US-11793812-B2 Methods of treating endometriosis SUMITOMO PHARMA SWITZERLAND GMBH (CH) 2023-10-24 US disclosed
US-20230317700-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-10-05 US disclosed
US-20230265173-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES ZYMEWORKS BC INC. (CA) 2023-08-24 US disclosed
CN-110312512-B Methods for treating uterine fibroids and endometriosis 梦欧文科学有限责任公司 2023-05-09 CN disclosed
US-6150391-A Diazabicyclo-octane derivatives as 5-HT receptor ligands MERCK SHARP & DOHME LTD. 2000-11-21 US disclosed
US-6096735-A Benzoheterocyclic derivatives OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-01 US disclosed
WO-1997028162-A1 DIAZABICYCLO-OCTANE DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1997-08-07 WO disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
US-5397798-A Benzamide and sulfonamide hypoglycemic agents ELI LILLY AND COMPANY (US) 1995-03-14 US disclosed
EP-0491525-A1 Benzamide and sulfonamide hypoglycemic agents ELI LILLY AND COMPANY (US) 1992-06-24 EP disclosed
US-4673668-A ANTICANCER AGENTS SUMITOMO PHARMACEUTICALS COMPANY (JP) 1987-06-16 US disclosed
EP-0107486-B1 AMINONAPHTHACENE DERIVATIVES AND THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-04-29 EP disclosed
EP-0107486-A1 Aminonaphthacene derivatives and their production SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-05-02 EP disclosed
US-4304772-A Ethanocarbazole derivatives and antidepressant compositions AYERST, MCKENNA & HARRISON, INC. (CA) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265173-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES MPST, TPST2, SULT1A1 ALDH1A1 1011/4885TSHR 2211/4885TDP1 2877/4885
US-11957684-B2 Treatment of heavy menstrual bleeding associated with uterine fibroids GNRHR, SHBG, FSHR ALDH1A1 658/4885TSHR 304/4885TDP1 3365/4885
US-11918583-B2 SHBG, GNRHR, FSHR ALDH1A1 592/4885TSHR 312/4885TDP1 3207/4885
US-11793812-B2 Methods of treating endometriosis GNRHR, SHBG, FSHR ALDH1A1 617/4885TSHR 262/4885TDP1 3233/4885
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 ALDH1A1 3393/4885TSHR 4613/4885TDP1 291/4885
US-20240165118-A1 Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids GNRHR, SHBG, FSHR ALDH1A1 658/4885TSHR 304/4885TDP1 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.